semaglutide gastric stasis lawyer in dallas Weight Loss Drug Weight-Loss Drug Stomach Paralysis Lawsuit
Description
2023 Sep 10;21(3):15593258231200527
In patients with T2DM who do not have atherosclerotic cardiovascular disease (ASCVD)/indicators of high-risk, HF, or CKD and who need to minimize hypoglycemia and/or promote weight loss, GLP-1 RAs are generally recommended as a second or third-line option as add-on to metformin therapy
This Templates item is sold by TemplateLabs
Glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptor agonists are increasingly used in the management of type 2 diabetes mellitus and obesity due to their ability to stimulate insulin secretion, delay gastric emptying, and suppress appetite
Results After weighting, 24817 adults used a GLP-1 receptor agonist (mean age 59.9 years
